Weight Loss and GLP-1 Jabs: Programming for Trainers

GLP-1 and dual-agonist "weight-loss jabs" — semaglutide, tirzepatide and the like — are changing the fat-loss landscape. Clients arrive lighter, hungry less often, and sometimes weaker. For personal trainers the opportunity is clear: pair effective medication with intelligent training and nutrition so the weight lost is mostly fat, fitness improves, and strength is protected (Wilding et al., 2021; Jastreboff et al., 2022).

What the drugs do

These medicines reduce appetite, slow gastric emptying and improve glycaemia, driving large weight loss — often 15–25% (Jastreboff et al., 2022). That loss includes fat mass and some lean mass, so coaching has to prioritise muscle retention (Look et al., 2025; Rochira et al., 2024).

The lean-mass question

Across the STEP (semaglutide) and SURMOUNT (tirzepatide) trials, DXA data show substantial fat loss alongside smaller but real lean-mass loss (Wilding et al., 2021; Look et al., 2025). That's not unique to the jabs — dieting alone also reduces lean mass and absolute VO₂max — but structured exercise limits the damage (Weiss et al., 2017). Build your plan assuming lean-mass risk, and train against it.

Exercise is the force multiplier

Randomised data show that combining GLP-1 therapy with supervised exercise beats either alone for the quality of weight loss and health markers — reducing abdominal obesity and inflammation and supporting bone health (Sandsdal et al., 2023; Jensen et al., 2024). Practically, that means:

• 2–3 weekly full-body resistance sessions, plus
• 150–300 minutes a week of mixed-modal aerobic work, scaled to training age and side-effect profile.

Programming priorities

• Resistance training first. Keep or build strength with 6–12 hard sets per muscle per week, using compound lifts and progressive overload. Resistance training during an energy deficit helps preserve lean mass (Lopez et al., 2022).
• Aerobic conditioning. Maintain or raise VO₂max with intervals and tempo work; dieting without training can drop cardiorespiratory fitness (Weiss et al., 2017).
• Protein targets. Push total daily protein towards ~1.6 g/kg/day — younger adults often need at least that to maximise lean-mass retention with lifting — spread across 3–5 meals at 0.3–0.5 g/kg per feeding (Nunes et al., 2022; Bagheri et al., 2023; Zhao et al., 2024).
• Bone and connective tissue. Include loaded carries, jumps and landings as tolerated, and heavy lower-body work; combining exercise with medication appears to preserve bone better than medication alone (Jensen et al., 2024).
• Side-effect-aware coaching. Early nausea and fatigue are common. Use shorter sessions, RPE-based progression and steady hydration.
• Maintenance planning. When doses reduce or stop, weight-regain risk rises. Habit-based exercise and continued activity support improve maintenance after the medication (Jensen et al., 2024; Horn et al., 2025).

What to tell clients

• The jab helps you eat less; training tells your body what to keep.
• We'll protect muscle, strength and fitness — expect structured resistance training, purposeful cardio and a protein plan.
• This is long term. Obesity is chronic, so training and nutrition skills are your "forever tools", with or without medication.

Weight-loss jabs are powerful. Trainers who integrate resistance training, aerobic conditioning, protein-forward nutrition and bone-protective loading will turn "less weight" into more health and performance. That's the competitive edge — and the ethical one.

References

• Bagheri, R. et al. (2023) 'Effects of 8 weeks of resistance training with different protein intakes', Biology of Sport.
• Horn, D.B. et al. (2025) 'Tirzepatide for maintenance of weight reduction', Obesity Reviews.
• Jastreboff, A.M. et al. (2022) 'Tirzepatide once weekly for the treatment of obesity', NEJM.
• Jensen, S.B.K. et al. (2024) 'Healthy weight loss maintenance with exercise, GLP-1 RA, or both', eClinicalMedicine.
• Jensen, S.B.K. et al. (2024) 'Bone health after exercise alone, GLP-1 RA, or both', JAMA Network Open.
• Lopez, P. et al. (2022) 'Resistance training and body composition', Sports Medicine.
• Look, M. et al. (2025) 'Body composition changes with tirzepatide (SURMOUNT-1)', Diabetes, Obesity and Metabolism.
• Nunes, E.A. et al. (2022) 'Protein intake to support resistance training-induced gains', Journal of Cachexia, Sarcopenia and Muscle.
• Rochira, V. et al. (2024) 'Tirzepatide and body composition', Nutrients.
• Sandsdal, R.M. et al. (2023) 'Combination of exercise and GLP-1 RA', Cardiovascular Diabetology.
• Weiss, E.P. et al. (2017) 'Effects of weight loss on lean mass, strength, and VO₂max', Medicine & Science in Sports & Exercise.
• Wilding, J.P.H. et al. (2021) 'Once-weekly semaglutide in adults with overweight or obesity (STEP 1)', NEJM.